Welcome to our dedicated page for Unity Btech news (Ticker: UBX), a resource for investors and traders seeking the latest updates and insights on Unity Btech stock.
Unity Biotechnology, Inc. has focused on developing therapeutics intended to slow, halt or reverse diseases of aging, including medicines that selectively eliminate or modulate senescent cells in age-related ophthalmologic and neurologic diseases. Company news has centered on UBX1325 (foselutoclax), an intravitreal BCL-xL inhibitor studied for diabetic macular edema, and clinical updates from the ASPIRE and BEHOLD studies.
Recurring updates also cover presentations and publications of retinal-disease data, quarterly financial results, cash-burn reduction, strategic alternatives for UBX1325 and related Tie2/anti-VEGF and Tie2 agonistic antibody assets, and board or governance changes tied to the company's biotechnology pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
UNITY Biotechnology announced positive results from the Phase 2 BEHOLD study of UBX1325, an investigational treatment for diabetic macular edema (DME). A single injection led to a statistically significant improvement in Best Corrected Visual Acuity (BCVA) of +6.2 ETDRS letters over 48 weeks. Approximately 53% of treated patients did not require additional injections during this period. Additionally, retinal structure remained stable as measured by central subfield thickness (CST). The treatment exhibited a favorable safety profile, with no intraocular inflammation observed. UNITY plans to advance to a Phase 2b DME study against aflibercept in the second half of 2023.
UNITY Biotechnology Program Update
UNITY Biotechnology (NASDAQ: UBX) is scheduled to host a program update on its lead program, UBX1325, focused on diseases of aging. The update will feature retinal expert Robert B. Bhisitkul, M.D., Ph.D. from UCSF, and will take place on April 24, 2023, at 5:00 a.m. PT/8:00 a.m. ET. The discussion is expected to cover potential therapeutic advancements in age-related ophthalmologic conditions, such as Diabetic Macular Edema (DME) and Age-related Macular Degeneration (AMD).
Investors can access the live webcast on UNITY's website, with a replay available shortly after. The company emphasizes its dedication to developing therapeutics aimed at selectively eliminating or modulating senescent cells to address age-related diseases. However, investors should remain cautious of the inherent risks and uncertainties in the clinical development process.